Schuster SJ - Search Results

1

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. Mato AR, et al. Among authors: schuster sj. Blood. 2016 Nov 3;128(18):2199-2205. doi: 10.1182/blood-2016-05-716977. Epub 2016 Sep 6. Blood. 2016. PMID: 27601462 Free article.

2

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.

Tsai D, Moore H, Hardy C, Porter D, Loh E, Vaughn D, Luger S, Schuster S, Stadtmauer E. Tsai D, et al. Bone Marrow Transplant. 1999 Sep;24(5):521-6. doi: 10.1038/sj.bmt.1701944. Bone Marrow Transplant. 1999. PMID: 10482937

3

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH. Porter DL, et al. Among authors: schuster sj. Biol Blood Marrow Transplant. 2001;7(4):230-8. doi: 10.1053/bbmt.2001.v7.pm11349810. Biol Blood Marrow Transplant. 2001. PMID: 11349810 Free article. Clinical Trial.

4

Acute myelogenous leukemia: advances and limitations of treatment.

Parisi E, Draznin J, Stoopler E, Schuster SJ, Porter D, Sollecito TP. Parisi E, et al. Among authors: schuster sj. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Mar;93(3):257-63. doi: 10.1067/moe.2002.121988. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002. PMID: 11925533 Review.

5

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.

Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA. Cohen AD, et al. Among authors: schuster sj. Bone Marrow Transplant. 2002 Jul;30(1):23-8. doi: 10.1038/sj.bmt.1703602. Bone Marrow Transplant. 2002. PMID: 12105773

6

High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation.

Hagen EA, Stern H, Porter D, Duffy K, Foley K, Luger S, Schuster SJ, Stadtmauer EA, Schuster MG. Hagen EA, et al. Among authors: schuster sj, schuster mg. Clin Infect Dis. 2003 Jan 1;36(1):9-15. doi: 10.1086/344906. Epub 2002 Dec 11. Clin Infect Dis. 2003. PMID: 12491195

7

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.

Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH. Laport GG, et al. Among authors: schuster sj. Blood. 2003 Sep 15;102(6):2004-13. doi: 10.1182/blood-2003-01-0095. Epub 2003 May 22. Blood. 2003. PMID: 12763934 Free article. Clinical Trial.

8

Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation.

Gerecitano J, Mathias C, Mick R, Duffy KM, Luger S, Stadtmauer EA, Schuster SJ, Tsai D, Nasta S, Berlin J, Phillips DK, High KA, Porter DL. Gerecitano J, et al. Among authors: schuster sj. J Hematother Stem Cell Res. 2003 Apr;12(2):215-23. doi: 10.1089/152581603321628359. J Hematother Stem Cell Res. 2003. PMID: 12804180

9

Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.

Tsai DE, Maillard I, Schuster SJ, Nasta SD, Porter DL, Klumpp TR, Goldenberg DM, Luger SM, Alavi A, Sharkey RM, Hartzell KB, Stadtmauer EA. Tsai DE, et al. Among authors: schuster sj. Clin Lymphoma. 2003 Jun;4(1):56-9. doi: 10.3816/clm.2003.n.015. Clin Lymphoma. 2003. PMID: 12837157

10

Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.

Loren AW, Luger SM, Stadtmauer EA, Tsai DE, Schuster S, Nasta SD, Goldstein SC, Perl A, Orloff G, Oliver JC, Green J, Emerson SG, Porter DL. Loren AW, et al. Bone Marrow Transplant. 2005 May;35(9):921-6. doi: 10.1038/sj.bmt.1704887. Bone Marrow Transplant. 2005. PMID: 15765118

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

254 results

Search Page